RICHMOND, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it completed its private placement offering as part of its January 15, 2014 announced alternative public offering ("APO"). Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "EKSO."
"We are pleased at the interest we have received from investors in this APO financing." said Nathan Harding, the Company's Chief Executive Officer. "We originally targeted a financing in the range of $12-20 million. Given the level of interest from qualified individual and institutional investors we increased our offering to just over $30 million. We now have a large and committed investor base and will continue to define the industry for exoskeletons and develop break-through technology."
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible.
Ekso Bionics' lead product, Ekso™, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.
Steven Sherman, the Company's Chairman added, "I am very proud of the initial success of the Ekso in rehabilitation centers worldwide, as well as the recent surge of media awareness that explores the range of possibilities for bionic robots. We see a future with wearable robots that enable people to walk again, as well as enhance their daily lives."
With this closing, the Company has raised a total in gross proceeds of $30,300,000 through the sale of 30,300,000 units at a price of $1.00 per share. Each unit includes one share of the Company's common stock and a warrant to purchase one share of the Company's common stock at an exercise price of $2.00 per share for a five-year period. After giving effect to the final closing, there are approximately 78,500,000 shares of Company common stock outstanding.
Gottbetter Capital Markets, LLC was the exclusive placement agent for the offering, and EDI Financial, Inc. was a sub-agent. Lead investors included Opaleye L.P. and Montrose Capital Partners. Further details on the APO financing can be found in the Company's 8-K filing on January 23, 2014.
The securities issued in the merger and sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under, or exemption from registration under, such Act.
About Ekso Bionics
Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on January 23, 2014. The Company does not undertake to update these forward-looking statements.